178 related articles for article (PubMed ID: 16905643)
1. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia.
St Sauver JL; Jacobson DJ; McGree ME; Lieber MM; Jacobsen SJ
Am J Epidemiol; 2006 Oct; 164(8):760-8. PubMed ID: 16905643
[TBL] [Abstract][Full Text] [Related]
2. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
4. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota.
Burke JP; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
Urology; 2006 Jan; 67(1):22-5. PubMed ID: 16413325
[TBL] [Abstract][Full Text] [Related]
6. Correlations between longitudinal changes in transitional zone volume and measures of benign prostatic hyperplasia in a population-based cohort.
St Sauver JL; Jacobson DJ; Girman CJ; McGree ME; Lieber MM; Jacobsen SJ
Eur Urol; 2006 Jul; 50(1):105-11. PubMed ID: 16466847
[TBL] [Abstract][Full Text] [Related]
7. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
Platz EA; Rohrmann S; Pearson JD; Corrada MM; Watson DJ; De Marzo AM; Landis PK; Metter EJ; Carter HB
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):390-6. PubMed ID: 15734963
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2006 Mar; 66(4):392-404. PubMed ID: 16302261
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
11. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia.
Burke JP; Rhodes T; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
Am J Epidemiol; 2006 Jul; 164(1):41-6. PubMed ID: 16611664
[TBL] [Abstract][Full Text] [Related]
12. Consultation patterns in a community survey of men with benign prostatic hyperplasia.
Simpson RJ; Lee RJ; Garraway WM; King D; McIntosh I
Br J Gen Pract; 1994 Nov; 44(388):499-502. PubMed ID: 7538316
[TBL] [Abstract][Full Text] [Related]
13. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer.
Roberts RO; Jacobson DJ; Girman CJ; Rhodes T; Lieber MM; Jacobsen SJ
Mayo Clin Proc; 2002 Mar; 77(3):219-25. PubMed ID: 11888024
[TBL] [Abstract][Full Text] [Related]
14. Prevention of benign prostatic hyperplasia disease.
Marks LS; Roehrborn CG; Andriole GL
J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
16. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men.
Mullan RJ; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ; Roberts RO
Urology; 2006 Feb; 67(2):300-5. PubMed ID: 16461080
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal changes in peak urinary flow rates in a community based cohort.
Roberts RO; Jacobsen SJ; Jacobson DJ; Rhodes T; Girman CJ; Lieber MM
J Urol; 2000 Jan; 163(1):107-13. PubMed ID: 10604326
[TBL] [Abstract][Full Text] [Related]
18. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
19. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
20. A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic diseases using transrectal sonography.
Ukimura O; Kojima M; Inui E; Ochiai A; Hata Y; Watanabe M; Saitoh M; Watanabe H
J Urol; 1996 Nov; 156(5):1673-8. PubMed ID: 8863568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
